

| Каталожный номер | HX126206 |
|---|---|
| Описание |
Anti-Human CLDN18.2 (SPX-101) (HX126206) is a research-grade recombinant antibody targeting Claudin-18. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Реактивность видов | Human |
| Применения | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Хозяинский вид | Human |
| Клоональность | Monoclonal |
| Изотип | IgG |
| ID клона | SPX-101 |
| Цель | CLDN18.2, Claudin-18.2 |
| Уровень эндотоксинов | < 10 EU/mg |
| Чистота | >95% as determined by SDS-PAGE. |
| Очистка | Protein A/G purified from cell culture supernatant. |
| Номер доступа | P56856-2 |
| Форма | Liquid |
| Буфер хранения | 0.01M PBS pH 7.4. Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии. |
| Устойчивость и хранение | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Альтернативные названия | SPX-101, SPX101, SPX101 |
| Фон | Claudin-18 (CLDN18.2) is a ~27 kDa protein. Involved in alveolar fluid homeostasis via regulation of alveolar epithelial tight junction composition and therefore ion transport and solute permeability, potentially via downstream regulation of the actin cytoskeleton organization and beta-2-adrenergic signaling. Required for lung alveolarization and maintenance of the paracellular alveolar epithelial barrier. Acts to maintain epithelial progenitor cell proliferation and organ size, via regulation of YAP1 localization away from the nucleus and thereby restriction of YAP1 target gene transcription. Acts as a negative regulator of RANKL-induced osteoclast differentiation, potentially via relocation of TJP2/ZO-2 away from the nucleus, subsequently involved in bone resorption in response to calcium deficiency. Mediates the osteoprotective effects of estrogen, potentially via acting downstream of estrogen signaling independently of RANKL signaling pathways. CLDN18.2 is the therapeutic target of zolbetuximab (Vyloy). |
| Примечание | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human CLDN18.2 (SPX-101)




Свяжитесь с нами для индивидуальных предложений, оптовых запросов и других вопросов.
Почта: [email protected]


+86-027-65523339
Building C, No. 666, Shen Dun Si Lu, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский